Newsroom

BioCytics Awarded a G-Rex^® Grant from ScaleReady™

PR Newswire

BioCytics is pleased to announce it has been awarded a $100,000 G-Rex^® grant from ScaleReady. This grant was given in support of BioCytics' efforts to develop and optimize a cGMP G-Rex^®-based manufacturing process to produce immune cell fractions that are a major component of BioCytics' platform therapy to treat tumors.

ScaleReady and Bio-Techne Announce Optimal Closed System Cytokine Packaged for Single Step Use in Closed System G-Rex^® Manufacture of CAR-T and TCR Therapies

Bio-Techne

ST. PAUL, Minn., Sept. 16, 2024 /PRNewswire/ -- ScaleReady and Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of the G-Rex^® optimized ProPakTM GMP Cytokines, ideally tailored to high efficiency closed system cell and gene-modified cell therapy (CGT) manufacturing.

ScaleReady announces the inaugural G-Rex^® Grant has been awarded to Stanford Medicine Laboratory for Cell and Gene Medicine

Bio-Techne

ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex^® Grant

ScaleReady Announces $20 Million G-Rex^® Grant Program for the Advancement of Cell and Gene Therapy (CGT) Development and Manufacturing

PR Newswire

The G-Rex^® Grant Program will provide academic and commercial institutions engaged in IND enabling pre-clinical research, process development, and/or ongoing GMP manufacturing of cell and gene therapies with the material resources and services needed to implement or optimize a highly efficient G-Rex^® based cell manufacturing platform.

CTMC partners with ScaleReady to automate, close, and scale for greater patient accessibility

PharmiWeb

The agreement will enable CTMC to strategically scale the recently completed GMP facility to drive high-throughput manufacturing utilizing the automated, closed system capabilities of the Fresenius Kabi Lovo^® and Cue^® cell processing systems.

Cellular Origins Partners With ScaleReady to Simplify, Standardize, and Automate Cell Therapy Manufacturing

Business Wire

Partnership aims to integrate ScaleReady’s CGT manufacturing workflow with Cellular Origins’ robotic technology Initially focussed on automation of ScaleReady’s G-Rex^® platform

Marker Therapeutics Announces Entry into Services Agreement with Wilson Wolf

HOUSTON, April 26, 2022 (GLOBE NEWSWIRE) -- -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of…

ScaleReady Launches Second Generation of Wilson Wolf G-Rex^® Product

The second generation G-Rex^®500M-CS improves on the materials and ergonomics of the original G-Rex^® while retaining the same cell expansion performance. St. Paul, MN, November 10, 2021 – ScaleReady announced…

ScaleReady hosts ISCT Symposium on Intelligent Scale-up

youtube.com

ScaleReady recruited a prestigious panel of cell therapy manufacturing experts to discuss their experiences and strategies for commercial scale up and scale out. The panel featured: Juan Vera, MD James…

ScaleReady Launches

Business Wire

ScaleReady launches with the mission to make cell and gene therapy manufacturing practical and viable. Through a partnership between Bio-Techne, Fresenius Kabi, and Wilson Wolf, ScaleReady is able to provide…

Joint Venture formed by Bio-Techne, Fresenius Kabi, and Wilson Wolf

Bio-Techne

The joint venture focuses on providing scalable manufacturing technologies needed to develop and commercialize new cell and gene therapies. Each partner contributes industry-leading products and unique expertise to the new…